Interest in "smart bombs" explodes.
D000080044:Ado-Trastuzumab Emtansine; D000617:Aminoglycosides / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D000079963:Brentuximab Vedotin; D005260:Female; D000079982:Gemtuzumab; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D018796:Immunoconjugates / Q000494:pharmacology / Q000627:therapeutic use*; D008453:Maytansine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D063268:Sialic Acid Binding Ig-like Lectin 3 / Q000187:drug effects / Q000378:metabolism; D000068878:Trastuzumab
D000617:Aminoglycosides; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C571163:CD33 protein, human; D018796:Immunoconjugates; D063268:Sialic Acid Binding Ig-like Lectin 3; D008453:Maytansine; D000079963:Brentuximab Vedotin; D000079982:Gemtuzumab; D000068878:Trastuzumab; D000080044:Ado-Trastuzumab Emtansine